Cargando…
Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan
OBJECTIVE: Whether a low-density lipoprotein cholesterol (LDL-C) goal is essential in secondary prevention is still being debated. The aim of our study was to investigate whether achieving particular LDL-C level goals is associated with the reduction in the risk of major adverse cardiac events (MACE...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658082/ https://www.ncbi.nlm.nih.gov/pubmed/29073192 http://dx.doi.org/10.1371/journal.pone.0186861 |
_version_ | 1783273929255682048 |
---|---|
author | Yeh, Yen-Ting Yin, Wei-Hsian Tseng, Wei-Kung Lin, Fang-Ju Yeh, Hung-I Chen, Jaw-Wen Wu, Yen-Wen Wu, Chau-Chung |
author_facet | Yeh, Yen-Ting Yin, Wei-Hsian Tseng, Wei-Kung Lin, Fang-Ju Yeh, Hung-I Chen, Jaw-Wen Wu, Yen-Wen Wu, Chau-Chung |
author_sort | Yeh, Yen-Ting |
collection | PubMed |
description | OBJECTIVE: Whether a low-density lipoprotein cholesterol (LDL-C) goal is essential in secondary prevention is still being debated. The aim of our study was to investigate whether achieving particular LDL-C level goals is associated with the reduction in the risk of major adverse cardiac events (MACEs) in patients with atherosclerotic cardiovascular diseases (ASCVD) on statin therapy. METHODS AND RESULTS: From January 2010 to August 2014, a total of 4099 patients with ASCVD in the Taiwan Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) registry were analyzed. The risk of a MACE was lower in patients with LDL-C level under control at < 100 mg/dL by statins than in patients with LDL-C level ≥100 mg/dL whether on statin therapy (hazard ratio [HR] 1.66, 95% confidence interval [CI] 1.04‒2.63, p = 0.03) or not (HR 2.04, 95% CI 1.06‒3.94, p = 0.03). In multivariate Cox model analyses, statin intensity had no significant predictive value, and LDL-C ≥ 100 mg/dL was associated with a slight but not significant trend toward increased risk of MACEs (HR 1.41, 95% CI 0.96‒2.07, p = 0.08). CONCLUSIONS: For patients with ASCVD on statin therapy guided by a target-driven strategy, failure to control LDL-C levels to < 100 mg/dL was associated with higher risk of MACEs. Statin intensity alone had no significant impact on the risk of MACEs after multivariate adjustment. |
format | Online Article Text |
id | pubmed-5658082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56580822017-11-09 Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan Yeh, Yen-Ting Yin, Wei-Hsian Tseng, Wei-Kung Lin, Fang-Ju Yeh, Hung-I Chen, Jaw-Wen Wu, Yen-Wen Wu, Chau-Chung PLoS One Research Article OBJECTIVE: Whether a low-density lipoprotein cholesterol (LDL-C) goal is essential in secondary prevention is still being debated. The aim of our study was to investigate whether achieving particular LDL-C level goals is associated with the reduction in the risk of major adverse cardiac events (MACEs) in patients with atherosclerotic cardiovascular diseases (ASCVD) on statin therapy. METHODS AND RESULTS: From January 2010 to August 2014, a total of 4099 patients with ASCVD in the Taiwan Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) registry were analyzed. The risk of a MACE was lower in patients with LDL-C level under control at < 100 mg/dL by statins than in patients with LDL-C level ≥100 mg/dL whether on statin therapy (hazard ratio [HR] 1.66, 95% confidence interval [CI] 1.04‒2.63, p = 0.03) or not (HR 2.04, 95% CI 1.06‒3.94, p = 0.03). In multivariate Cox model analyses, statin intensity had no significant predictive value, and LDL-C ≥ 100 mg/dL was associated with a slight but not significant trend toward increased risk of MACEs (HR 1.41, 95% CI 0.96‒2.07, p = 0.08). CONCLUSIONS: For patients with ASCVD on statin therapy guided by a target-driven strategy, failure to control LDL-C levels to < 100 mg/dL was associated with higher risk of MACEs. Statin intensity alone had no significant impact on the risk of MACEs after multivariate adjustment. Public Library of Science 2017-10-26 /pmc/articles/PMC5658082/ /pubmed/29073192 http://dx.doi.org/10.1371/journal.pone.0186861 Text en © 2017 Yeh et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Yeh, Yen-Ting Yin, Wei-Hsian Tseng, Wei-Kung Lin, Fang-Ju Yeh, Hung-I Chen, Jaw-Wen Wu, Yen-Wen Wu, Chau-Chung Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan |
title | Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan |
title_full | Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan |
title_fullStr | Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan |
title_full_unstemmed | Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan |
title_short | Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan |
title_sort | lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: which matters in the real world? statin intensity or low-density lipoprotein cholesterol level? ‒ data from a multicenter registry cohort study in taiwan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658082/ https://www.ncbi.nlm.nih.gov/pubmed/29073192 http://dx.doi.org/10.1371/journal.pone.0186861 |
work_keys_str_mv | AT yehyenting lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT yinweihsian lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT tsengweikung lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT linfangju lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT yehhungi lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT chenjawwen lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT wuyenwen lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT wuchauchung lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan AT lipidloweringtherapyinpatientswithatheroscleroticcardiovasculardiseaseswhichmattersintherealworldstatinintensityorlowdensitylipoproteincholesterolleveldatafromamulticenterregistrycohortstudyintaiwan |